Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 168

1.

Review article: Novel technologies in the treatment and monitoring of advanced and relapsed epithelial ovarian cancer.

Cunnea P, Gowers S, Moore JE Jr., Drakakis E, Boutelle M, Fotopoulou C.

Converg Sci Phys Oncol. 2017;3. pii: 013002. doi: 10.1088/2057-1739/aa5cf1. Epub 2017 Feb 23.

2.

Impact of Phosphoproteomics in the Era of Precision Medicine for Prostate Cancer.

Ramroop JR, Stein MN, Drake JM.

Front Oncol. 2018 Feb 16;8:28. doi: 10.3389/fonc.2018.00028. eCollection 2018. Review.

3.

Multigene Profiling of CTCs in mCRPC Identifies a Clinically Relevant Prognostic Signature.

Singhal U, Wang Y, Henderson J, Niknafs YS, Qiao Y, Gursky A, Zaslavsky A, Chung JS, Smith DC, Karnes RJ, Chang SL, Feng FY, Palapattu GS, Taichman RS, Chinnaiyan AM, Tomlins SA, Morgan TM.

Mol Cancer Res. 2018 Apr;16(4):643-654. doi: 10.1158/1541-7786.MCR-17-0539. Epub 2018 Feb 16.

PMID:
29453313
4.

Circulating tumor cells in genitourinary tumors.

Massari F, Di Nunno V, Comito F, Cubelli M, Ciccarese C, Iacovelli R, Fiorentino M, Montironi R, Ardizzoni A.

Ther Adv Urol. 2017 Nov 22;10(2):65-77. doi: 10.1177/1756287217742564. eCollection 2018 Feb. Review.

5.

Evaluation of PD-L1 expression on vortex-isolated circulating tumor cells in metastatic lung cancer.

Dhar M, Wong J, Che J, Matsumoto M, Grogan T, Elashoff D, Garon EB, Goldman JW, Sollier Christen E, Di Carlo D, Kulkarni RP.

Sci Rep. 2018 Feb 7;8(1):2592. doi: 10.1038/s41598-018-19245-w.

6.

Synaptophysin expression on circulating tumor cells in patients with castration resistant prostate cancer undergoing treatment with abiraterone acetate or enzalutamide.

Pal SK, He M, Chen L, Yang L, Pillai R, Twardowski P, Hsu J, Kortylewski M, Jones JO.

Urol Oncol. 2018 Apr;36(4):162.e1-162.e6. doi: 10.1016/j.urolonc.2017.12.006. Epub 2017 Dec 27.

PMID:
29289429
7.

Circulating Tumor Cell Number as a Response Measure of Prolonged Survival for Metastatic Castration-Resistant Prostate Cancer: A Comparison With Prostate-Specific Antigen Across Five Randomized Phase III Clinical Trials.

Heller G, McCormack R, Kheoh T, Molina A, Smith MR, Dreicer R, Saad F, de Wit R, Aftab DT, Hirmand M, Limon A, Fizazi K, Fleisher M, de Bono JS, Scher HI.

J Clin Oncol. 2018 Feb 20;36(6):572-580. doi: 10.1200/JCO.2017.75.2998. Epub 2017 Dec 22.

8.

Establishment and Application of Prostate Cancer Circulating Tumor Cells in the Era of Precision Medicine.

Suh YS, Joung JY, Kim SH, Seo HK, Chung J, Lee KH.

Biomed Res Int. 2017;2017:7206307. doi: 10.1155/2017/7206307. Epub 2017 Nov 5. Review.

9.

Improved EGFR mutation detection using combined exosomal RNA and circulating tumor DNA in NSCLC patient plasma.

Krug AK, Enderle D, Karlovich C, Priewasser T, Bentink S, Spiel A, Brinkmann K, Emenegger J, Grimm DG, Castellanos-Rizaldos E, Goldman JW, Sequist LV, Soria JC, Camidge DR, Gadgeel SM, Wakelee HA, Raponi M, Noerholm M, Skog J.

Ann Oncol. 2018 Mar 1;29(3):700-706. doi: 10.1093/annonc/mdx765.

10.

Isolation of circulating tumor cells from pancreatic cancer by automated filtration.

Brychta N, Drosch M, Driemel C, Fischer JC, Neves RP, Esposito I, Knoefel W, Möhlendick B, Hille C, Stresemann A, Krahn T, Kassack MU, Stoecklein NH, von Ahsen O.

Oncotarget. 2017 Sep 16;8(49):86143-86156. doi: 10.18632/oncotarget.21026. eCollection 2017 Oct 17.

11.

Circulating cell-free DNA and circulating tumor cells, the "liquid biopsies" in ovarian cancer.

Cheng X, Zhang L, Chen Y, Qing C.

J Ovarian Res. 2017 Nov 13;10(1):75. doi: 10.1186/s13048-017-0369-5. Review.

12.

Circulating Tumor Cells as an Auxiliary Diagnostic Tool in Surgery.

Kolostova K, Rzechonek A, Schützner J, Grill R, Lischke R, Hladik P, Simonek J, Bobek V.

In Vivo. 2017 Nov-Dec;31(6):1197-1202.

13.

Further the liquid biopsy: Gathering pieces of the puzzle of genometastasis theory.

García-Casas A, García-Olmo DC, García-Olmo D.

World J Clin Oncol. 2017 Oct 10;8(5):378-388. doi: 10.5306/wjco.v8.i5.378. Review.

14.

The role of biomarkers in the management of bone-homing malignancies.

D'Oronzo S, Brown J, Coleman R.

J Bone Oncol. 2017 Sep 11;9:1-9. doi: 10.1016/j.jbo.2017.09.001. eCollection 2017 Nov. Review.

15.

Glycan Stimulation Enables Purification of Prostate Cancer Circulating Tumor Cells on PEDOT NanoVelcro Chips for RNA Biomarker Detection.

Shen MY, Chen JF, Luo CH, Lee S, Li CH, Yang YL, Tsai YH, Ho BC, Bao LR, Lee TJ, Jan YJ, Zhu YZ, Cheng S, Feng FY, Chen P, Hou S, Agopian V, Hsiao YS, Tseng HR, Posadas EM, Yu HH.

Adv Healthc Mater. 2018 Feb;7(3). doi: 10.1002/adhm.201700701. Epub 2017 Sep 11.

PMID:
28892262
16.

Liquid biopsy in patients with hepatocellular carcinoma: Circulating tumor cells and cell-free nucleic acids.

Okajima W, Komatsu S, Ichikawa D, Miyamae M, Ohashi T, Imamura T, Kiuchi J, Nishibeppu K, Arita T, Konishi H, Shiozaki A, Morimura R, Ikoma H, Okamoto K, Otsuji E.

World J Gastroenterol. 2017 Aug 21;23(31):5650-5668. doi: 10.3748/wjg.v23.i31.5650. Review.

17.

Circulating tumor cells: silent predictors of metastasis.

Zhou L, Dicker DT, Matthew E, El-Deiry WS, Alpaugh RK.

F1000Res. 2017 Aug 14;6. pii: F1000 Faculty Rev-1445. doi: 10.12688/f1000research.11313.1. eCollection 2017. Review.

18.

Circulating Tumor Cells: Moving Biological Insights into Detection.

Chen L, Bode AM, Dong Z.

Theranostics. 2017 Jun 25;7(10):2606-2619. doi: 10.7150/thno.18588. eCollection 2017. Review.

19.

Circulating tumor cells in prostate cancer: Precision diagnosis and therapy.

Liu W, Yin B, Wang X, Yu P, Duan X, Liu C, Wang B, Tao Z.

Oncol Lett. 2017 Aug;14(2):1223-1232. doi: 10.3892/ol.2017.6332. Epub 2017 Jun 7.

20.

Overcoming Oncogenic Mediated Tumor Immunity in Prostate Cancer.

Bryant G, Wang L, Mulholland DJ.

Int J Mol Sci. 2017 Jul 17;18(7). pii: E1542. doi: 10.3390/ijms18071542. Review.

Supplemental Content

Support Center